Evidence map›Paper›PMID 35998338›Full record

ArticleChronic obstructive pulmonary diseases (Miami, Fla.)2022

Impact of the Coronavirus Disease 2019 Pandemic on Physical and Mental Health of Patients With COPD: Results From a Longitudinal Cohort Study Conducted in the United States (2020-2021).

William Z Zhang, Stephanie L LaBedz, Janet T Holbrook, Andrew Gangemi, Ramasubramanian Baalachandran, Michelle N Eakin, Robert A Wise, Kaharu Sumino, American Lung Association Airways Clinical Research Centers

Abstract read
In one paragraph

Article in Chronic obstructive pulmonary diseases (Miami, Fla.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

William Z ZhangDivision of Pulmonary and Critical Care Medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York, New York, United States.
Stephanie L LaBedzDivision of Pulmonary, Critical Care, Sleep, and Allergy, University of Illinois at Chicago, Chicago, Illinois, United States.
Janet T HolbrookCenter for Clinical Trials and Evidence Synthesis, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States.
Andrew GangemiDepartment of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, United States.
Ramasubramanian BaalachandranPulmonary and Critical Care Medicine, University of Vermont, Burlington, Vermont, United States.
Michelle N EakinDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States.
Robert A WiseDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States.
Kaharu SuminoDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri, United States.
American Lung Association Airways Clinical Research Centers

Funding

Network Management Core (NEMO) for the Pulmonary Trials Cooperative (PTC)U01HL128954 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SCIURBA, FRANK, WISNIEWSKI, STEPHEN R · 2015 to 2019
$17.0M
Effect of Losartan on Progression of EmphysemaU01HL128951 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI HOLBROOK, JANET T., WISE, ROBERT A. · 2015 to 2019
$1.8M
Postdoctoral Training Program in Pulmonary and Critical Care Translational ResearchT32HL144909 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI DUDEK, STEVEN M, FINN, PATRICIA W · 2019 to 2023
$1.3M
American Lung AssociationNHLBI NIH HHS T32 HL144909NHLBI NIH HHS U01HL128951NHLBI NIH HHS U01HL128954
6 · The paper itself

Abstract

Background: Patients with chronic obstructive pulmonary disease (COPD) are at higher risk for severe coronavirus disease 2019 (COVID-19). From the pandemic's onset there has been concern regarding effects on health and well-being of high-risk patients. Methods: This was an ancillary study to the Losartan Effects on Emphysema Progression (LEEP) Trial and was designed to collect descriptive information longitudinally about the health and wellbeing of COPD patients who were enrolled in a clinical trial. Participants were interviewed by telephone about their health status every 2 weeks and their mental health, knowledge, and behaviors every 8 weeks from June 2020 to April 2021. There were no pre-specified hypotheses. Results: We enrolled 157 of the 220 participants from the parent LEEP trial. Their median age was 69 years, 55% were male, and 82% were White; median forced expiratory volume in 1 second (FEV Conclusion: Our select cohort of moderate to severe COPD patients who were well integrated into a health care network coped well with the COVID-19 pandemic. Few participants were diagnosed with COVID-19, levels of depression and anxiety were stable, most adopted accepted risk reduction behaviors, and did not become socially isolated; most were vaccinated by the end of 2021.

Indexed as

anxietyCOPDCOVID-19depressionvaccinationvaccine hesitancy

Identifiers

PMID35998338
PMCPMC9718577

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.